Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2000 - 2003
  • Medical Resident, Medicine, Duke University 1997 - 2000
  • M.D., University of Zagreb (Croatia) 1985
• 

  Previous Appointments & Affiliations

  • Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1997 - 2017
  • Assistant Professor in Surgery, Neurosurgery, Neurosurgery 2012 - 2017
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2017
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2013
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2007 - 2012
  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2003 - 2007
• Research
• 

  Selected Grants

  • Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells awarded by National Institutes of Health 2013 - 2018
  • Mentored Clinical Research Scholar Program awarded by National Institutes of Health 2002 - 2006
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • O’Reilly, Eileen M., Do-Youn Oh, Neesha Dhani, Daniel J. Renouf, Myung Ah Lee, Weijing Sun, George Fisher, et al. “Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.” Jama Oncol 5, no. 10 (October 1, 2019): 1431–38. https://doi.org/10.1001/jamaoncol.2019.1588.
       Full Text  Link to Item
    • Knox, J., A. Cheng, S. Cleary, P. Galle, N. Kokudo, R. Lencioni, J. Park, et al. “A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.” Ann Oncol 30 Suppl 4 (July 2019): iv51. https://doi.org/10.1093/annonc/mdz155.186.
       Full Text  Link to Item
    • Knox, J., A. Cheng, S. Cleary, P. Galle, N. Kokudo, R. Lencioni, J. Park, et al. “A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2.” Ann Oncol 30 Suppl 4 (July 2019): iv59–60. https://doi.org/10.1093/annonc/mdz155.216.
       Full Text  Link to Item
    • Fujiwara, Yutaka, Haruo Iguchi, Noboru Yamamoto, Manabu Hayama, Masahiro Nii, Shinya Ueda, Keiko Komuro, Mariko Sugimoto, Gordana Vlahovic, and Toshiyuki Kozuki. “Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.” Cancer Sci 110, no. 5 (May 2019): 1715–23. https://doi.org/10.1111/cas.14003.
       Full Text  Link to Item
    • Affronti, Mary Lou, Jennifer Gamboa Jackman, Frances McSherry, James E. Herndon, Elwood C. Massey, Eric Lipp, Annick Desjardins, et al. “Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.” Oncologist 23, no. 8 (August 2018): 889-e98. https://doi.org/10.1634/theoncologist.2018-0149.
       Full Text  Link to Item
    • Desjardins, Annick, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, et al. “Recurrent Glioblastoma Treated with Recombinant Poliovirus.” N Engl J Med 379, no. 2 (July 12, 2018): 150–61. https://doi.org/10.1056/NEJMoa1716435.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.
       Full Text  Link to Item
    • Omuro, Antonio, Gordana Vlahovic, Michael Lim, Solmaz Sahebjam, Joachim Baehring, Timothy Cloughesy, Alfredo Voloschin, et al. “Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.” Neuro Oncol 20, no. 5 (April 9, 2018): 674–86. https://doi.org/10.1093/neuonc/nox208.
       Full Text  Link to Item
    • Reap, Elizabeth A., Carter M. Suryadevara, Kristen A. Batich, Luis Sanchez-Perez, Gary E. Archer, Robert J. Schmittling, Pamela K. Norberg, et al. “Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.” Cancer Res 78, no. 1 (January 1, 2018): 256–64. https://doi.org/10.1158/0008-5472.CAN-17-0469.
       Full Text  Link to Item
    • Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.” J Neurooncol 134, no. 2 (September 2017): 363–69. https://doi.org/10.1007/s11060-017-2535-4.
       Full Text  Link to Item
    • Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, et al. “Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.” Clin Cancer Res 23, no. 8 (April 15, 2017): 1898–1909. https://doi.org/10.1158/1078-0432.CCR-16-2057.
       Full Text  Link to Item
    • Dunn-Pirio, Anastasie M., and Gordana Vlahovic. “Immunotherapy approaches in the treatment of malignant brain tumors.” Cancer 123, no. 5 (March 1, 2017): 734–50. https://doi.org/10.1002/cncr.30371.
       Full Text  Link to Item
    • Dowlati, Afshin, Gordana Vlahovic, Ronald B. Natale, Erik Rasmussen, Indrajeet Singh, Yuying C. Hwang, John Rossi, Michael B. Bass, Gregory Friberg, and Cheryl A. Pickett. “A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.” Clin Cancer Res 22, no. 18 (September 15, 2016): 4574–84. https://doi.org/10.1158/1078-0432.CCR-15-2145.
       Full Text  Link to Item
    • Farber, S Harrison, Vadim Tsvankin, Jessica L. Narloch, Grace J. Kim, April K. S. Salama, Gordana Vlahovic, Kimberly L. Blackwell, John P. Kirkpatrick, and Peter E. Fecci. “Embracing rejection: Immunologic trends in brain metastasis.” Oncoimmunology 5, no. 7 (July 2016): e1172153. https://doi.org/10.1080/2162402X.2016.1172153.
       Full Text  Link to Item
    • Desjardins, Annick, Gordana Vlahovic, and Henry S. Friedman. “Vaccine Therapy, Oncolytic Viruses, and Gliomas.” Oncology (Williston Park) 30, no. 3 (March 2016): 211–18.
       Link to Item
    • Gurzadyan, V. G., H. Yan, G. Vlahovic, A. Kashin, P. Killela, Z. Reitman, S. Sargsyan, G. Yegorian, G. Milledge, and B. Vlahovic. “Detecting somatic mutations in genomic sequences by means of Kolmogorov-Arnold analysis.” R Soc Open Sci 2, no. 8 (August 2015): 150143. https://doi.org/10.1098/rsos.150143.
       Full Text  Link to Item
    • Vlahovic, Gordana, Peter E. Fecci, David Reardon, and John H. Sampson. “Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.” Neuro Oncol 17, no. 8 (August 2015): 1043–45. https://doi.org/10.1093/neuonc/nov071.
       Full Text  Link to Item
    • Smith, David C., Thea Kalebic, Jeffrey R. Infante, Lillian L. Siu, Daniel Sullivan, Gordana Vlahovic, John S. Kauh, et al. “Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.” Invest New Drugs 33, no. 3 (June 2015): 652–63. https://doi.org/10.1007/s10637-015-0230-x.
       Full Text  Link to Item
    • Desjardins, A., J. Herndon, F. McSherry, A. Ravelo, E. Lipp, P. Healy, K. Peters, et al. “AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12–13. https://doi.org/10.1093/neuonc/nou237.20.
       Full Text
    • Desjardins, A., J. Herndon, F. McSherry, A. Ravelo, E. Lipp, P. Healy, S. Boulton, et al. “AT-19 * SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12–v12. https://doi.org/10.1093/neuonc/nou237.19.
       Full Text
    • Desjardins, A., J. Sampson, K. Peters, G. Vlahovic, S. Threatt, J. Herndon, S. Boulton, et al. “AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13–v13. https://doi.org/10.1093/neuonc/nou237.21.
       Full Text
    • Ghiaseddin, A., A. Dunn-Pirio, K. Peters, G. Vlahovic, J. Herndon, S. Threatt, J. Sampson, A. Friedman, H. Friedman, and A. Desjardins. “AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13–v13. https://doi.org/10.1093/neuonc/nou237.22.
       Full Text
    • Kang, J., A. Desjardins, P. Healy, J. Herndon, E. Lipp, K. Peters, G. Vlahovic, et al. “SM-02 * LEVETIRACETAM USAGE IN POST-OPERATIVE SEIZURE MANAGEMENT IN MALIGNANT GLIOMA.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v206–v206. https://doi.org/10.1093/neuonc/nou277.2.
       Full Text
    • Mowery, Y., A. Wright, A. Desjardins, K. Peters, T. Ranjan, G. Vlahovic, H. Friedman, et al. “MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v130–31. https://doi.org/10.1093/neuonc/nou260.18.
       Full Text
    • Ranjan, T., K. B. Peters, G. Vlahovic, J. Watts, S. Dutton, S. Boulton, E. Lipp, et al. “AT-48 * A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v19–v19. https://doi.org/10.1093/neuonc/nou237.47.
       Full Text
    • Razis, E., G. Vlahovic, L. Recht, H. Wheeler, D. Reardon, P. G. Fisher, S. Owen, et al. “IT-28 * VACCINATION AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III IN GLIOBLASTOMA: THE RINDOPEPIMUT COMPASSIONATE USE EXPERIENCE.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v115–16. https://doi.org/10.1093/neuonc/nou258.26.
       Full Text
    • Vlahovic, G., G. Archer, D. Lally-Goss, E. Reap, K. Batich, A. Desjardins, K. Peters, et al. “IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v117–v117. https://doi.org/10.1093/neuonc/nou258.32.
       Full Text
    • Vlahovic, Gordana, Vassiliki Karantza, Ding Wang, David Cosgrove, Nikita Rudersdorf, Jianning Yang, Hao Xiong, Todd Busman, and Mack Mabry. “A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.” Invest New Drugs 32, no. 5 (October 2014): 976–84. https://doi.org/10.1007/s10637-014-0116-3.
       Full Text  Link to Item
    • Sampson, John H., and Gordana Vlahovic. “Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial".” Neuro Oncol 16, no. 2 (January 2014): 169–70. https://doi.org/10.1093/neuonc/not311.
       Full Text  Link to Item
    • Zhang, Tian, Shiva K. Das, Diane R. Fels, Katherine S. Hansen, Terence Z. Wong, Mark W. Dewhirst, and Gordana Vlahovic. “PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.” Ajr Am J Roentgenol 201, no. 5 (November 2013): W698–706. https://doi.org/10.2214/AJR.12.9698.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.
       Full Text  Link to Item
    • Rodgers, George M., Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, et al. “Cancer- and chemotherapy-induced anemia.” J Natl Compr Canc Netw 10, no. 5 (May 2012): 628–53. https://doi.org/10.6004/jnccn.2012.0064.
       Full Text  Link to Item
    • Miskovic, Marijana, Tanja Lalic, Danijela Radivojevic, Sanja Cirkovic, Gordana Vlahovic, Dragan Zamurovic, and Marija Guc-Scekic. “Lower incidence of deletions in the survival of motor neuron gene and the neuronal apoptosis inhibitory protein gene in children with spinal muscular atrophy from Serbia.” Tohoku J Exp Med 225, no. 3 (November 2011): 153–59. https://doi.org/10.1620/tjem.225.153.
       Full Text  Link to Item
    • Herbst, Roy S., Rafat Ansari, Frederique Bustin, Patrick Flynn, Lowell Hart, Gregory A. Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula O’Connor, and John Hainsworth. “Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.” Lancet 377, no. 9780 (May 28, 2011): 1846–54. https://doi.org/10.1016/S0140-6736(11)60545-X.
       Full Text  Link to Item
    • Shetty, Vivekananda, Gomathinayagam Sinnathamby, Zacharie Nickens, Punit Shah, Julie Hafner, Lisa Mariello, Shivali Kamal, et al. “MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.” J Proteomics 74, no. 5 (May 1, 2011): 728–43. https://doi.org/10.1016/j.jprot.2011.02.020.
       Full Text  Link to Item
    • Michael, M., G. Vlahovic, K. Khamly, K. J. Pierce, F. Guo, and A. J. Olszanski. “Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.” Br J Cancer 103, no. 10 (November 9, 2010): 1554–61. https://doi.org/10.1038/sj.bjc.6605941.
       Full Text  Link to Item
    • Stevenson, Marvaretta, William Mostertz, Chaitanya Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, et al. “Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.” Clin Cancer Res 15, no. 24 (December 15, 2009): 7553–61. https://doi.org/10.1158/1078-0432.CCR-09-1939.
       Full Text  Link to Item
    • Goudar, Ranjit K., and Gordana Vlahovic. “Hypoxia, angiogenesis, and lung cancer.” Curr Oncol Rep 10, no. 4 (July 2008): 277–82. https://doi.org/10.1007/s11912-008-0043-6.
       Full Text  Link to Item
    • Wong, Terence Z., Jeffrey L. Lacy, Neil A. Petry, Thomas C. Hawk, Thomas A. Sporn, Mark W. Dewhirst, and Gordana Vlahovic. “PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator.” Ajr Am J Roentgenol 190, no. 2 (February 2008): 427–32. https://doi.org/10.2214/AJR.07.2876.
       Full Text  Link to Item
    • Vlahovic, G., A. M. Ponce, Z. Rabbani, F. K. Salahuddin, L. Zgonjanin, I. Spasojevic, Z. Vujaskovic, and M. W. Dewhirst. “Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.” Br J Cancer 97, no. 6 (September 17, 2007): 735–40. https://doi.org/10.1038/sj.bjc.6603941.
       Full Text  Link to Item
    • Willett, Christopher G., Dan G. Duda, Emmanuelle di Tomaso, Yves Boucher, Brian G. Czito, Zeljko Vujaskovic, Gordana Vlahovic, et al. “Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.” Nat Clin Pract Oncol 4, no. 5 (May 2007): 316–21. https://doi.org/10.1038/ncponc0813.
       Full Text  Link to Item
    • Vlahovic, G., Z. N. Rabbani, J. E. Herndon, M. W. Dewhirst, and Z. Vujaskovic. “Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.” Br J Cancer 95, no. 8 (October 23, 2006): 1013–19. https://doi.org/10.1038/sj.bjc.6603366.
       Full Text  Open Access Copy  Link to Item
    • Marjanović, Borivoj, Milena Durić, Dragan Zamurović, Ruzica Kravljanac, Gordana Vlahović, and Dijana Komazec. “[Aetiological aspects of West Syndrome].” Srp Arh Celok Lek 134 Suppl 1 (May 2006): 45–49. https://doi.org/10.2298/sarh06s1045m.
       Full Text  Link to Item
    • Vlahovic, Gordana, and Jeffrey Crawford. “Activation of tyrosine kinases in cancer.” Oncologist 8, no. 6 (2003): 531–38. https://doi.org/10.1634/theoncologist.8-6-531.
       Full Text  Link to Item
    • Stajić, N., V. Rajić, D. Zdravković, B. Marjanović, D. Zamurović, Z. Gujanica, G. Vlahović, and R. Bogdanović. “[Schimke immuno-osseous dysplasia].” Srp Arh Celok Lek 129 Suppl 1 (2001): 63–67.
       Link to Item
    • Vlahovic, G., M. L. Russell, R. R. Mercer, and J. D. Crapo. “Cellular and connective tissue changes in alveolar septal walls in emphysema.” Am J Respir Crit Care Med 160, no. 6 (December 1999): 2086–92. https://doi.org/10.1164/ajrccm.160.6.9706031.
       Full Text  Link to Item

  • Book Sections

    • Khagi, S., and G. Vlahovic. “Immunotherapy Clinical Trials in Neuro-Oncology.” In Translational Immunotherapy of Brain Tumors, 181–210, 2017. https://doi.org/10.1016/B978-0-12-802420-1.00008-9.
       Full Text
    • Fecci, P. E., K. Riccione, G. P. Dunn, E. Reap, G. Vlahovic, K. Congdon, and J. H. Sampson. “Immunotherapy for gliomas.” In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 91–120, 2016. https://doi.org/10.1017/CBO9781107588721.006.
       Full Text

  • Other Articles

    • Stevenson, Marvaretta, William Mostertz, Chaitanya R. Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, et al. “Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.” Clin Cancer Res, March 15, 2012. https://doi.org/10.1158/1078-0432.CCR-12-0337.
       Full Text  Link to Item

  • Conference Papers

    • Weller, M., G. Vlahovic, M. Khasraw, A. A. Brandes, R. Zwirtes, K. Tatsuoka, A. F. Carpentier, D. A. Reardon, and M. Bent. “A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548.” In Annals of Oncology, 27:vi113, 2016. https://doi.org/10.1093/annonc/mdw367.34.
       Full Text
    • Peters, K., D. Randazzo, M. Affronti, E. Lipp, F. McSherry, J. Herndon, C. Flahiff, et al. “QL-20 PROGNOSTIC IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AND FATIGUE IN NEWLY DIAGNOSED GLIOBLASTOMA.” In Neuro Oncology, 16:v182–v182. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou269.19.
       Full Text  Link to Item
    • Peters, K., D. Reardon, D. Randazzo, S. Dutton, A. Edwards, E. Lipp, J. Herndon, et al. “AT-46 VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL.” In Neuro Oncology, 16:v18–v18. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou237.45.
       Full Text  Link to Item
    • Randazzo, D., M. Affronti, E. Lipp, F. McSherry, J. Herndon, C. Flahiff, E. Miller, et al. “QL-21 SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS.” In Neuro Oncology, 16:v182–83. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou269.20.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.